Cargando…
Efficacy of Super-Bioavailable Itraconazole and Conventional Itraconazole at Different Dosing Regimens in Glabrous Tinea Infection - A Randomized Clinical Trial
INTRODUCTION: Itraconazole follows non-linear pharmacokinetics and hence is recommended once daily, but in real-world practice, is commonly prescribed as twice daily. Hence, this study aimed to evaluate the efficacy and safety of super-bioavailable-itraconazole-130 mg (SB-130) and conventional-itrac...
Autores principales: | , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10520254/ https://www.ncbi.nlm.nih.gov/pubmed/37766823 http://dx.doi.org/10.2147/DDDT.S421583 |
_version_ | 1785109877344960512 |
---|---|
author | Shenoy, Manjunath M De, Abhishek Shah, Bela Das, Anupam Saraswat, Abir Lahiri, Koushik Yadav, Sheetal Sarda, Aarti Chakraborty, Disha J, Dharmender Kamat, Shruti Doshi, Yashika Gonsalves, Nelry Choudhary, Ankita Dhoot, Dhiraj Mahadkar, Namrata Bhushan, Sumit Gadkari, Rujuta Barkate, Hanmant |
author_facet | Shenoy, Manjunath M De, Abhishek Shah, Bela Das, Anupam Saraswat, Abir Lahiri, Koushik Yadav, Sheetal Sarda, Aarti Chakraborty, Disha J, Dharmender Kamat, Shruti Doshi, Yashika Gonsalves, Nelry Choudhary, Ankita Dhoot, Dhiraj Mahadkar, Namrata Bhushan, Sumit Gadkari, Rujuta Barkate, Hanmant |
author_sort | Shenoy, Manjunath M |
collection | PubMed |
description | INTRODUCTION: Itraconazole follows non-linear pharmacokinetics and hence is recommended once daily, but in real-world practice, is commonly prescribed as twice daily. Hence, this study aimed to evaluate the efficacy and safety of super-bioavailable-itraconazole-130 mg (SB-130) and conventional-itraconazole-200 mg (CITZ-200) once daily compared with conventional-itraconazole-100 mg (CITZ-100) twice daily in glabrous tinea. METHODS: A total of 261 eligible patients were enrolled in this prospective, randomized, clinical study from December-2021 to August-2022 at seven centers in India. Efficacy and safety assessments were done at week-3 and 6, with follow-up at week-10 for relapse. The primary objective was to assess the proportion of patients who achieved complete cure at week-6 following treatment in all itraconazole groups. The secondary outcomes were safety and clinical and mycological cure rates. RESULTS: Of 261 patients, 240 were included in the analysis. At week-6, 140 patients were completely cured; thus, overall cure rate was 58.33%. Fifty-five patients (69%) in SB-130 while 47/77 (61%) and 38/83 (46%) patients were completely cured in CITZ-200 and CITZ-100 groups respectively (p<0.05; SB-130: CITZ-100, p=0.32; SB-130: CITZ-200, p=0.058; CITZ-200: CITZ-100). There was no statistical difference in the mycological cure rate and area clearance rate between any of the groups (p=0.14); however, a statistically significant difference was noted for OD dosing over BD dosing in achieving clinical cure rates (p<0.05). A total of 13/140 patients (9%) relapsed following complete cure, with no statistically significant difference between any of the groups (p=0.50). All treatments were safe and well-tolerated, with no discontinuation. CONCLUSION: In this clinical study, moderate efficacy with all doses of ITZ was reported but was better with OD dosing. Although there was no statistical difference between SB-130 and CITZ-200, SB-130 may be preferred over CITZ-200 owing to the advantage of SB over the conventional ITZ. |
format | Online Article Text |
id | pubmed-10520254 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-105202542023-09-27 Efficacy of Super-Bioavailable Itraconazole and Conventional Itraconazole at Different Dosing Regimens in Glabrous Tinea Infection - A Randomized Clinical Trial Shenoy, Manjunath M De, Abhishek Shah, Bela Das, Anupam Saraswat, Abir Lahiri, Koushik Yadav, Sheetal Sarda, Aarti Chakraborty, Disha J, Dharmender Kamat, Shruti Doshi, Yashika Gonsalves, Nelry Choudhary, Ankita Dhoot, Dhiraj Mahadkar, Namrata Bhushan, Sumit Gadkari, Rujuta Barkate, Hanmant Drug Des Devel Ther Original Research INTRODUCTION: Itraconazole follows non-linear pharmacokinetics and hence is recommended once daily, but in real-world practice, is commonly prescribed as twice daily. Hence, this study aimed to evaluate the efficacy and safety of super-bioavailable-itraconazole-130 mg (SB-130) and conventional-itraconazole-200 mg (CITZ-200) once daily compared with conventional-itraconazole-100 mg (CITZ-100) twice daily in glabrous tinea. METHODS: A total of 261 eligible patients were enrolled in this prospective, randomized, clinical study from December-2021 to August-2022 at seven centers in India. Efficacy and safety assessments were done at week-3 and 6, with follow-up at week-10 for relapse. The primary objective was to assess the proportion of patients who achieved complete cure at week-6 following treatment in all itraconazole groups. The secondary outcomes were safety and clinical and mycological cure rates. RESULTS: Of 261 patients, 240 were included in the analysis. At week-6, 140 patients were completely cured; thus, overall cure rate was 58.33%. Fifty-five patients (69%) in SB-130 while 47/77 (61%) and 38/83 (46%) patients were completely cured in CITZ-200 and CITZ-100 groups respectively (p<0.05; SB-130: CITZ-100, p=0.32; SB-130: CITZ-200, p=0.058; CITZ-200: CITZ-100). There was no statistical difference in the mycological cure rate and area clearance rate between any of the groups (p=0.14); however, a statistically significant difference was noted for OD dosing over BD dosing in achieving clinical cure rates (p<0.05). A total of 13/140 patients (9%) relapsed following complete cure, with no statistically significant difference between any of the groups (p=0.50). All treatments were safe and well-tolerated, with no discontinuation. CONCLUSION: In this clinical study, moderate efficacy with all doses of ITZ was reported but was better with OD dosing. Although there was no statistical difference between SB-130 and CITZ-200, SB-130 may be preferred over CITZ-200 owing to the advantage of SB over the conventional ITZ. Dove 2023-09-21 /pmc/articles/PMC10520254/ /pubmed/37766823 http://dx.doi.org/10.2147/DDDT.S421583 Text en © 2023 Shenoy et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Shenoy, Manjunath M De, Abhishek Shah, Bela Das, Anupam Saraswat, Abir Lahiri, Koushik Yadav, Sheetal Sarda, Aarti Chakraborty, Disha J, Dharmender Kamat, Shruti Doshi, Yashika Gonsalves, Nelry Choudhary, Ankita Dhoot, Dhiraj Mahadkar, Namrata Bhushan, Sumit Gadkari, Rujuta Barkate, Hanmant Efficacy of Super-Bioavailable Itraconazole and Conventional Itraconazole at Different Dosing Regimens in Glabrous Tinea Infection - A Randomized Clinical Trial |
title | Efficacy of Super-Bioavailable Itraconazole and Conventional Itraconazole at Different Dosing Regimens in Glabrous Tinea Infection - A Randomized Clinical Trial |
title_full | Efficacy of Super-Bioavailable Itraconazole and Conventional Itraconazole at Different Dosing Regimens in Glabrous Tinea Infection - A Randomized Clinical Trial |
title_fullStr | Efficacy of Super-Bioavailable Itraconazole and Conventional Itraconazole at Different Dosing Regimens in Glabrous Tinea Infection - A Randomized Clinical Trial |
title_full_unstemmed | Efficacy of Super-Bioavailable Itraconazole and Conventional Itraconazole at Different Dosing Regimens in Glabrous Tinea Infection - A Randomized Clinical Trial |
title_short | Efficacy of Super-Bioavailable Itraconazole and Conventional Itraconazole at Different Dosing Regimens in Glabrous Tinea Infection - A Randomized Clinical Trial |
title_sort | efficacy of super-bioavailable itraconazole and conventional itraconazole at different dosing regimens in glabrous tinea infection - a randomized clinical trial |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10520254/ https://www.ncbi.nlm.nih.gov/pubmed/37766823 http://dx.doi.org/10.2147/DDDT.S421583 |
work_keys_str_mv | AT shenoymanjunathm efficacyofsuperbioavailableitraconazoleandconventionalitraconazoleatdifferentdosingregimensinglabroustineainfectionarandomizedclinicaltrial AT deabhishek efficacyofsuperbioavailableitraconazoleandconventionalitraconazoleatdifferentdosingregimensinglabroustineainfectionarandomizedclinicaltrial AT shahbela efficacyofsuperbioavailableitraconazoleandconventionalitraconazoleatdifferentdosingregimensinglabroustineainfectionarandomizedclinicaltrial AT dasanupam efficacyofsuperbioavailableitraconazoleandconventionalitraconazoleatdifferentdosingregimensinglabroustineainfectionarandomizedclinicaltrial AT saraswatabir efficacyofsuperbioavailableitraconazoleandconventionalitraconazoleatdifferentdosingregimensinglabroustineainfectionarandomizedclinicaltrial AT lahirikoushik efficacyofsuperbioavailableitraconazoleandconventionalitraconazoleatdifferentdosingregimensinglabroustineainfectionarandomizedclinicaltrial AT yadavsheetal efficacyofsuperbioavailableitraconazoleandconventionalitraconazoleatdifferentdosingregimensinglabroustineainfectionarandomizedclinicaltrial AT sardaaarti efficacyofsuperbioavailableitraconazoleandconventionalitraconazoleatdifferentdosingregimensinglabroustineainfectionarandomizedclinicaltrial AT chakrabortydisha efficacyofsuperbioavailableitraconazoleandconventionalitraconazoleatdifferentdosingregimensinglabroustineainfectionarandomizedclinicaltrial AT jdharmender efficacyofsuperbioavailableitraconazoleandconventionalitraconazoleatdifferentdosingregimensinglabroustineainfectionarandomizedclinicaltrial AT kamatshruti efficacyofsuperbioavailableitraconazoleandconventionalitraconazoleatdifferentdosingregimensinglabroustineainfectionarandomizedclinicaltrial AT doshiyashika efficacyofsuperbioavailableitraconazoleandconventionalitraconazoleatdifferentdosingregimensinglabroustineainfectionarandomizedclinicaltrial AT gonsalvesnelry efficacyofsuperbioavailableitraconazoleandconventionalitraconazoleatdifferentdosingregimensinglabroustineainfectionarandomizedclinicaltrial AT choudharyankita efficacyofsuperbioavailableitraconazoleandconventionalitraconazoleatdifferentdosingregimensinglabroustineainfectionarandomizedclinicaltrial AT dhootdhiraj efficacyofsuperbioavailableitraconazoleandconventionalitraconazoleatdifferentdosingregimensinglabroustineainfectionarandomizedclinicaltrial AT mahadkarnamrata efficacyofsuperbioavailableitraconazoleandconventionalitraconazoleatdifferentdosingregimensinglabroustineainfectionarandomizedclinicaltrial AT bhushansumit efficacyofsuperbioavailableitraconazoleandconventionalitraconazoleatdifferentdosingregimensinglabroustineainfectionarandomizedclinicaltrial AT gadkarirujuta efficacyofsuperbioavailableitraconazoleandconventionalitraconazoleatdifferentdosingregimensinglabroustineainfectionarandomizedclinicaltrial AT barkatehanmant efficacyofsuperbioavailableitraconazoleandconventionalitraconazoleatdifferentdosingregimensinglabroustineainfectionarandomizedclinicaltrial |